| Property |
Value |
| Protein Name |
Sigma-1 Receptor |
| Gene |
SIGMAR1 |
| UniProt ID |
Q9Y6M5 |
| PDB ID |
5HK1, 5HI4, 6DJZ, 7MC6 |
| Molecular Weight |
~25 kDa (223 amino acids) |
| Subcellular Localization |
Endoplasmic reticulum, mitochondrial membrane |
| Protein Family |
Sigma receptor family, chaperone family |
The sigma-1 receptor (Sigmar1) is a unique transmembrane chaperone protein predominantly localized to the endoplasmic reticulum (ER) and mitochondrial membranes. It functions as a ligand-operated chaperone that modulates calcium signaling, ER stress responses, and mitochondrial function. Mutations in SIGMAR1 cause a rare form of juvenile-onset amyotrophic lateral sclerosis (ALS) and distal motor neuropathy, while common variants are associated with increased risk for sporadic ALS and frontotemporal dementia (FTD). This page covers Sigmar1 structure, normal neurological functions, disease mechanisms, and therapeutic potential.
The sigma-1 receptor is a 223-amino acid integral membrane protein:
¶ Domain Organization
- N-terminal region (residues 1-50): Proline-rich, involved in protein interactions
- Transmembrane domains (residues 51-80, 90-120): Two transmembrane helices
- Ligand-binding domain (residues 80-160): Hydrophobic pocket for agonist binding
- C-terminal region (residues 160-223): Chaperone domain, Ca2+ binding
- Transmembrane architecture: Type III membrane protein with two transmembrane helices
- Ligand binding: Binds a variety of ligands including (+)-pentazocine, SA4503, and donepezil
- Oligomerization: Forms homodimers and higher-order oligomers
- Ca2+ binding: C-terminal domain binds Ca2+ with moderate affinity
- PDZ-binding motif: C-terminal PDZ-binding sequence for protein interactions
- ER chaperone function: Helps fold and regulate ER-resident proteins
- Protein quality control: Targets misfolded proteins for degradation
- Calcium homeostasis: Modulates ER Ca2+ store release
- Mitochondrial dynamics: Regulates mitochondrial fission and fusion
- Bioenergetics: Maintains mitochondrial membrane potential
- Mitochondrial calcium: Modulates mitochondrial Ca2+ uptake
- ER stress response: Activates UPR signaling pathways
- Autophagy induction: Promotes clearance of protein aggregates
- Anti-apoptotic signaling: Blocks caspase activation
- Ion channel modulation: Regulates NMDA, potassium, and calcium channels
- Neurotransmitter systems: Modulates dopamine, serotonin, and glutamate signaling
- Synaptic plasticity: Involved in LTP and memory formation
- Lipid raft organization: Associates with lipid rafts
- Sphingolipid synthesis: Involved in ceramide metabolism
- Membrane remodeling: Regulates membrane protein trafficking
SIGMAR1 mutations cause a rare form of juvenile-onset ALS:
- Autosomal recessive inheritance
- E102Q mutation: Most common pathogenic variant
- Onset: Typically in second or third decade
- Phenotype: Progressive limb weakness, motor neuropathy
-
Loss of chaperone function
- Impaired ER stress response
- Accumulation of misfolded proteins
- Disrupted protein quality control
-
Mitochondrial dysfunction
- Impaired mitochondrial Ca2+ handling
- Reduced ATP production
- Increased ROS production
-
Calcium dysregulation
- Disrupted ER-mitochondria contact sites
- Altered Ca2+ signaling
- Excitotoxicity susceptibility
-
Autophagy impairment
- Reduced autophagic flux
- Protein aggregate accumulation
- Impaired mitophagy
- Genetic association: Common variants increase FTD risk
- TDP-43 pathology: Often co-occurs with TDP-43 inclusions
- Overlap with ALS: SIGMAR1 is an ALS-FTD gene
- SA4503: Selective agonist, neuroprotective in preclinical models
- PRE-084: Selective agonist, improves mitochondrial function
- Donepezil: Approved AD drug with Sigmar1 agonist activity
- Fluvoxamine: SSRI with Sigmar1 binding
-
ER stress mitigation
- Activates chaperone pathways
- Reduces pro-apoptotic signaling
- Promotes protein folding
-
Mitochondrial protection
- Maintains mitochondrial function
- Reduces ROS
- Preserves ATP levels
-
Calcium homeostasis
- Modulates ER-mitochondria coupling
- Reduces excitotoxicity
- Protects against Ca2+ dysregulation
-
Anti-inflammatory effects
- Reduces microglial activation
- Modulates neuroinflammation
- Donepezil: FDA-approved for AD, secondary Sigmar1 effects
- Cutamesine (SA4503): Completed phase II for ALS
- Novel agonists: Several in preclinical development
- Viral delivery: AAV vectors for SIGMAR1 overexpression
- Small molecules: Blood-brain barrier permeable agonists
- Combination therapy: Sigmar1 agonists with other neuroprotective agents
- Hayashi, T. & Su, T.P. (2007) Sigma-1 receptor chaperones at the ER-mitochondria interface (Journal of Cell Biology)
- Al-Saif, A. et al. (2011) A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis (Annals of Neurology)
- Matsumoto, R.R. et al. (2016) Sigma receptors: Potential targets for Parkinson's disease (Neuroscience & Biobehavioral Reviews)
- Ono, Y. et al. (2003) Neuroprotective effects of sigma-1 receptor ligands (Brain Research)